📣 Our new paper in @JNCCN: acquired resistance to #immunotherapy (ARI) across 11 tumor types
Reconstructed IPD: 15,199 pts / 41 phase 3 trials
• 73.5% develop ARI by 3y
• Higher CR/PR → less ARI, regardless of tumor type
ARI may be determined by response depth, not histology
Cheers to @DoniaMarco & @CCITdk 🇩🇰
Full paper 👇👇👇
2
7
18
1,834
CCIT-DK: National Center for Cancer Immune Therapy retweeted
📣 New in #EJC: among PD-(L)1 responders, durability tracks response depth, not tumor type
Our nationwide cohort 🇩🇰: 2,127 responders (#melanoma, #RCC, #NSCLC)
• Within CR & within PR, PFS near-identical across tumors
• PR vs CR = dominant factor
Two papers, two faces of the same coin 🪙:
response depth, not tumor type, drives the risk of acquired resistance to IO
Trial-level (@JNCCN) real-world (#EJC), same conclusion
Cheers to @DoniaMarco & @CCITdk
Full paper 👇👇
#LCSM#IO
4
4
12
724
CCIT-DK: National Center for Cancer Immune Therapy retweeted
In a recent interview, @holmstrom_mo of @CCITdk discussed the potential of therapeutic cancer vaccines in MPNs, highlighting the challenges of integrating vaccine strategies into treatment. 💉🩸
Click here to watch the full interview:
🎥 👉 ow.ly/cBWP50YXv1I#ESHMPN2026#MPNsm#ImmunoOnc#HemOnc
Acquired resistance to Cancer Immunotherapy
Free at bit.ly/4jptfZz
➡️ Metastatic cancers can be cured
➡️ Pts who initially respond can develop resistance (up to 65% of responders)
❗One of the top priorities in Oncology
Reviewed in @TrendsMolecMed@CCITdk@MdCurioni
2
1
5
250
CCIT-DK: National Center for Cancer Immune Therapy retweeted
📢The Copenhagen Symposium on T Cell Therapy and Cellular Engineering (CATC) 2024
⏰ 24-25 September 2024
📍 Greater Copenhagen, Denmark
More at
catc.dtu.dk/about
New publication on #MPNsm from @CCITdk published in @BrJHaem: Peripheral blood lymphocytes (PBL) from patients with CALR mutant #MPNsm display increased levels of surface TGFb and GARP. Probably mediated by enhanced binding of activated platelets to PBL.
doi.org/10.1111/bjh.19711
📣 Webinar "Adoptive cell immunotherapies for cancer"
SN Oncology Webinar Series on 14 May at 4 pm CEST by @SpringerNature
👉 Free registration at: cassyni.com/events/Y5qVZUYYn…
👩🔬 Speaker: Inge Marie Svane, Director of @CCITdk
👨🎓 Chair: Luca Danelli, Senior Editor @NatureComms
Despite manufacturing costs ~67 000 €, academic TIL therapy for patients with #melanoma is both cost-saving and cost-effective in 🇩🇰 and 🇱🇺
Publicly-funded #celltherapy can be sustainable!
New #JITC article: Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial bit.ly/3PG0IlP@DoniaMarco@tenHamR@HaanenJohn @ValescaRetel
5
28
2,601
CCIT-DK: National Center for Cancer Immune Therapy retweeted
Excited to share our latest article on @jitcancer, where we show that a TGFβ-based immune modulatory vaccine can both directly and indirectly modulate the phenotype of TAMs and CAFs, two high TGFβ-secreting cell subsets in the TME ➡ lnkd.in/dpyf9MPJ@CCITdk
1
4
12
1,772
CCIT-DK: National Center for Cancer Immune Therapy retweeted
📣 The Neoantigen Based Cancer Vaccine Pipeline at Dana Farber Cancer Institute
👨⚕️ by Derin Keskin bit.ly/42KN3yY
🕰 March 8th 2024 at 9.15
📍 Auditorium H2, Herlev Hospital, DK
💻Online at bit.ly/4bK1Lug
‼️Join this seminar, No registration required‼️
🔬 Murine Models for Cancer Immunotherapy, an analysis of tumor microenvironment (TME) compositions
🐭 Insights into comparative roles of the Lymphoid, Myeloid, and Stromal cell compartments of these models from the TSMI group here in @CCITdk
More at 👉 frontiersin.org/articles/10.…